This article was originally published in The Gray Sheet
Agency for Healthcare Research and Quality is circulating a 1draft guide for conducting comparative-effectiveness reviews of medical technology and treatments. The guide addresses key methodological issues and the assessment of evidence quality. Comparative-effectiveness research has become a hot topic among policymakers who see potential cost-savings from better informed treatment guidelines, and a Medicare package bill expected to be introduced this year could provide funding for a new comparative-effectiveness center (2"The Gray Sheet" Oct. 1, 2007, p. 12). Comments on AHRQ's draft guide are due Nov. 7
You may also be interested in...
Creating a national infrastructure for comparative effectiveness research has been flagged as a priority for inclusion in a Medicare package that Congress could consider before the end of the year
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.